Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Novo Nordisk's NN-9931?
NN-9931 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH)....
NN-9931 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
NN-9931 is under clinical development by Novo Nordisk and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
NN-9931 by Novo Nordisk for Liver Cirrhosis: Likelihood of Approval
NN-9931 is under clinical development by Novo Nordisk and currently in Phase II for Liver Cirrhosis. According to GlobalData, Phase...